# EDGAR Filing Document

**Accession Number:** 0000846475
**File Stem:** 0001104659-23-023588
**Filing Date:** 2023-2
**Character Count:** 9004
**Document Hash:** c3df992280a0448f8438be916d40ec2a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-023588.hdr.sgml**: 20230221

**ACCESSION NUMBER**: 0001104659-23-023588

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230216

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230221

**DATE AS OF CHANGE**: 20230221

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZYNEX INC
- **CENTRAL INDEX KEY:** 0000846475
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **IRS NUMBER:** 870403828
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38804
- **FILM NUMBER:** 23645638

**BUSINESS ADDRESS:**
- **STREET 1:** 9655 MAROON CIRCLE
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112
- **BUSINESS PHONE:** (800)-495-6670

**MAIL ADDRESS:**
- **STREET 1:** 9655 MAROON CIRCLE
- **CITY:** ENGLEWOOD
- **STATE:** CO
- **ZIP:** 80112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZYNEX MEDICAL HOLDINGS INC
- **DATE OF NAME CHANGE:** 20050812

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZYNEX MEDICAL HOLDINGS   INC
- **DATE OF NAME CHANGE:** 20040120

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FOX RIVER HOLDINGS  INC
- **DATE OF NAME CHANGE:** 20031126

?xml version="1.0" encoding="utf-8"?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 16, 2023

**<u>Zynex, Inc.</u>**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;<u><u>&nbsp;&nbsp;&nbsp;&nbsp;</u> <u>Nevada</u><u>&nbsp;&nbsp;&nbsp;&nbsp;</u></u> | &nbsp;&nbsp;<u><u>001-38804</u></u> | &nbsp;&nbsp;<u><u>90-0275169</u></u> |
| &nbsp;&nbsp;(State or other jurisdiction<br> of incorporation) | &nbsp;&nbsp;Commission File<br> Number | &nbsp;&nbsp; (I.R.S. Employer Identification<br> number) |

---

<u>9655 Maroon Circle, Englewood, CO 80112</u>

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: <u>(800) 495-6670</u>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Ticker symbol(s) | Name of each exchange on which<br> registered |
| Common Stock, $0.001 par value per share | ZYXI | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**ITEM 8.01 OTHER EVENTS**

On February 21, 2023, the Company issued a press release announcing the lease of a new 41,000 square foot facility to accommodate Zynex Monitoring Solution's (ZMS) current and expected future growth. The new ZMS facility is located within a quarter mile of Zynex Medical Headquarters on Maroon Drive in Englewood, Colorado, and the 66-month lease begins on July 1, 2023.

The full text of the press release is furnished herewith as Exhibit 99.1.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

d)&nbsp;&nbsp;&nbsp;&nbsp; <u>Exhibits</u>. The following exhibits are filed with this report.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [99.1](tm237389d1_ex99-1.htm) | [Zynex, Inc. Press Release dated February 21, 2023](tm237389d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: February 21, 2023

---

| |
|:---|
| ZYNEX, INC. |
| /s/ Dan Moorhead |
| Dan Moorhead |
| Chief Financial Officer |

---

## Exhibit 99.1

Exhibit 99.1

**Zynex Leases New Facility to Accommodate Growth**

ENGLEWOOD, Colo., February 21, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the lease of a new 41,000 square foot facility to accommodate Zynex Monitoring Solution's (ZMS) current and expected future growth.

"The considerable expansion of ZMS has led to the need for additional office, lab and production space," said Thomas Sandgaard, CEO and Founder of Zynex. "In the past year we've increased headcount in the monitoring division by 94%, and the growth is indicative of our commitment to the commercialization of our patient monitoring devices. We are looking forward to several upcoming regulatory submissions and believe the additional space will support the division for future developments."

The new ZMS facility is located within a quarter mile of Zynex Medical Headquarters on Maroon Drive in Englewood, Colorado, and the 66-month lease begins on July 1, 2023.

**About Zynex, Inc.** 

Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

**Safe Harbor Statement**

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain C.E. marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2021 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

**Contact: Zynex, Inc. (800) 495-6670** 

**Investor Relations Contact:**

Gilmartin Group

Investor Relations Counsel

ir@zynex.com

SOURCE Zynex